{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T10:52:31Z","timestamp":1773139951571,"version":"3.50.1"},"reference-count":25,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,10]]},"DOI":"10.1182\/bloodadvances.2025018454","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:56:54Z","timestamp":1765486614000},"page":"1559-1563","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Real-world evidence of measurable residual disease assessment in multiple myeloma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5851-3720","authenticated-orcid":false,"given":"Maria-Teresa","family":"Cedena","sequence":"first","affiliation":[{"name":"1Hematology Department, Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n imas12, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7535-3861","authenticated-orcid":false,"given":"Noemi","family":"Puig","sequence":"additional","affiliation":[{"name":"2Hematology Department, Hospital Universitario de Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca, Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1977-3815","authenticated-orcid":false,"given":"Bruno","family":"Paiva","sequence":"additional","affiliation":[{"name":"3Cancer Center Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada, Universidad de Navarra, Instituto de Investigaci\u00f3n Sanitaria de Navarra, Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9-Enrique","family":"de la Puerta","sequence":"additional","affiliation":[{"name":"4Hematology Department, Hospital Universitario Galdakao, Galdakao, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"P\u00e9rez-Monta\u00f1a","sequence":"additional","affiliation":[{"name":"5Hematology Department, Hospital Universitario Son Espases, Palma, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0784-7688","authenticated-orcid":false,"given":"Mar\u00eda","family":"Casanova","sequence":"additional","affiliation":[{"name":"6Hematology Department, Hospital Universitario Costa del Sol, Marbella, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaqu\u00edn","family":"Bre\u00f1a","sequence":"additional","affiliation":[{"name":"7Hematology Department, Hospital Universitario Nuestra Se\u00f1ora de la Candelaria, Santa Cruz Tenerife, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0006-4162","authenticated-orcid":false,"given":"Antoni","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"8Hematology Department, Hospital Universitario Arnau Vilanova, Lleida, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4451-1318","authenticated-orcid":false,"given":"Felipe","family":"de Arriba","sequence":"additional","affiliation":[{"name":"9Servicio de Hematolog\u00eda. Hospital Universitario Morales Meseguer, IMIB-Pascual Parrilla, Universidad de Murcia, Murcia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Mart\u00ednez-Chamorro","sequence":"additional","affiliation":[{"name":"10Hematology Department, Hospital Universitario Quir\u00f3nsalud, Madrid and Universidad Europea de Madrid, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maialen","family":"Sirvent","sequence":"additional","affiliation":[{"name":"11Hematology Department, Hospital Universitario Donostia, Donostia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria-Jes\u00fas","family":"Blanchard","sequence":"additional","affiliation":[{"name":"12Hematology Department, Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3774-118X","authenticated-orcid":false,"given":"Rafael","family":"Alonso","sequence":"additional","affiliation":[{"name":"1Hematology Department, Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n imas12, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8025-5112","authenticated-orcid":false,"given":"Miguel-\u00c1ngel","family":"\u00c1lvarez","sequence":"additional","affiliation":[{"name":"13Hematology Department, Hospital Universitario Reina Sof\u00eda, C\u00f3rdoba, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco-Javier","family":"Capote","sequence":"additional","affiliation":[{"name":"14Hematology Department, Hospital Universitario Puerta del Mar, C\u00e1diz, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricarda","family":"Garc\u00eda-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"15Hematology Department, Hospital Universitario Virgen de la Victoria, M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9-Juan","family":"P\u00e9rez","sequence":"additional","affiliation":[{"name":"2Hematology Department, Hospital Universitario de Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca, Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5236-7785","authenticated-orcid":false,"given":"Paula","family":"Rodriguez-Otero","sequence":"additional","affiliation":[{"name":"3Cancer Center Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada, Universidad de Navarra, Instituto de Investigaci\u00f3n Sanitaria de Navarra, Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3393-9570","authenticated-orcid":false,"given":"Juan-Jos\u00e9","family":"Lahuerta","sequence":"additional","affiliation":[{"name":"1Hematology Department, Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n imas12, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7908-0063","authenticated-orcid":false,"given":"Joaqu\u00edn","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[{"name":"1Hematology Department, Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n imas12, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Maria-Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"3Cancer Center Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada, Universidad de Navarra, Instituto de Investigaci\u00f3n Sanitaria de Navarra, Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9183-4857","authenticated-orcid":false,"given":"Jes\u00fas","family":"San-Miguel","sequence":"additional","affiliation":[{"name":"2Hematology Department, Hospital Universitario de Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca, Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"issue":"8","key":"2026030916214899700_bib1","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"5","key":"2026030916214899700_bib2","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1182\/blood.V99.5.1853","article-title":"Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome","volume":"99","author":"San Miguel","year":"2002","journal-title":"Blood"},{"issue":"9","key":"2026030916214899700_bib3","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2001-12-0297","article-title":"Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation","volume":"100","author":"Rawstron","year":"2002","journal-title":"Blood"},{"issue":"3","key":"2026030916214899700_bib4","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood-2011-07-370460","article-title":"High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma","volume":"119","author":"Paiva","year":"2012","journal-title":"Blood"},{"issue":"23","key":"2026030916214899700_bib5","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2026030916214899700_bib6","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1158\/2643-3230.BCD-23-0044","article-title":"Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel","volume":"4","author":"Paiva","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"6","key":"2026030916214899700_bib7","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood.2022016782","article-title":"MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials","volume":"141","author":"Paiva","year":"2023","journal-title":"Blood"},{"issue":"4","key":"2026030916214899700_bib8","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.2020010439","article-title":"Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE","volume":"139","author":"San-Miguel","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2026030916214899700_bib9","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41408-021-00498-0","article-title":"Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02\/HOVON 95 MM trial","volume":"11","author":"Oliva","year":"2021","journal-title":"Blood Cancer J"},{"issue":"10","key":"2026030916214899700_bib10","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1200\/JCO.20.01814","article-title":"Evaluation of sustained minimal residual disease negativity with daratumumab-combination regimens in relapsed and\/or refractory multiple myeloma: analysis of POLLUX and CASTOR","volume":"39","author":"Avet-Loiseau","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026030916214899700_bib11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood.2020006731","article-title":"Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma","volume":"137","author":"Goicoechea","year":"2021","journal-title":"Blood"},{"issue":"8","key":"2026030916214899700_bib12","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J Clin Oncol"},{"issue":"25","key":"2026030916214899700_bib13","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials","volume":"35","author":"Lahuerta","year":"2017","journal-title":"J Clin Oncol"},{"issue":"20","key":"2026030916214899700_bib14","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1200\/JCO.2012.46.2119","article-title":"Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX study","volume":"31","author":"Rawstron","year":"2013","journal-title":"J Clin Oncol"},{"issue":"25","key":"2026030916214899700_bib15","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2017.73.1331","article-title":"Minimal residual disease negativity is a new end point of myeloma therapy","volume":"35","author":"Harousseau","year":"2017","journal-title":"J Clin Oncol"},{"issue":"27","key":"2026030916214899700_bib16","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1200\/JCO.23.02771","article-title":"Curative strategy for high-risk smoldering myeloma: carfilzomib, lenalidomide, and dexamethasone (KRd) followed by transplant, KRd consolidation, and Rd maintenance","volume":"42","author":"Mateos","year":"2024","journal-title":"J Clin Oncol"},{"issue":"18","key":"2026030916214899700_bib17","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1182\/blood.2022019531","article-title":"Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma","volume":"142","author":"Rosi\u00f1ol","year":"2023","journal-title":"Blood"},{"issue":"25","key":"2026030916214899700_bib18","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026030916214899700_bib19","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41408-024-01156-x","article-title":"Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)","volume":"14","author":"Derman","year":"2024","journal-title":"Blood Cancer J"},{"issue":"4","key":"2026030916214899700_bib20","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood.2024024371","article-title":"EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma","volume":"144","author":"Landgren","year":"2024","journal-title":"Blood"},{"issue":"10","key":"2026030916214899700_bib21","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"issue":"19","key":"2026030916214899700_bib22","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.3390\/cancers13194924","article-title":"Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma","volume":"13","author":"Puig","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"2026030916214899700_bib23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ajh.27526","article-title":"Clinical significance of complete remission and measurable residual disease in relapsed\/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy","volume":"100","author":"Zabaleta","year":"2025","journal-title":"Am J Hematol"},{"issue":"suppl_1","key":"2026030916214899700_bib24","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1182\/blood-2019-125062","article-title":"Precision medicine based on the achievement of sustained undetectable minimal residual disease (MRD) by next-generation flow (NGF) and imaging leads to significant reduction in risk of progression of patients with multiple myeloma (MM)","volume":"134","author":"De La Puerta Rueda","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2026030916214899700_bib25","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/5\/1559\/2505975\/blooda_adv-2025-018454-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/5\/1559\/2505975\/blooda_adv-2025-018454-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T20:21:56Z","timestamp":1773087716000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/5\/1559\/557281\/Real-world-evidence-of-measurable-residual-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018454","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,10]]},"published":{"date-parts":[[2026,2,26]]}}}